Payment overview · 2025
General Payments
$1,331.72
60 reported records · 18 companies
Healthcare provider profile · identity verified
John Cherian, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BURGETTSTOWN, PA · NPI 1134381593
Verified facts
What the public records show
CMS Open Payments records show John Cherian, MD received $1,331.72 in general payments during 2025 across 60 reported records.
Novo Nordisk Inc accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Eliquis, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 946 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 367 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 946 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.81 | 12.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $158.27 | 11.9% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $150.52 | 11.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.74 | 10.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $131.35 | 9.9% | 6 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $119.16 | 8.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.30 | 7.2% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $66.51 | 5.0% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $65.20 | 4.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.91 | 3.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.61 | 2.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.71 | 2.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.27 | 2.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.91 | 1.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.98 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.43 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.32 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,331.72 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $180.53 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $158.27 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $142.74 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $138.69 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $131.35 | 6 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $123.89 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $119.16 | 3 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $95.30 | 6 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $65.20 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| CONFIRM RX Normalized: confirm rx |
Device | Abbott Laboratories | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.12 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.12 | 2 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 197 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 946 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 136 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
197 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
946 | 196 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
367 | 73 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
946 | 196 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1648 | 442 |
| Metoprolol Succinate | Metoprolol Succinate | 1445 | 385 |
| Clopidogrel | Clopidogrel Bisulfate | 972 | 248 |
| Eliquis | Apixaban | 946 | 196 |
| Potassium Chloride | Potassium Chloride | 891 | 211 |
| Furosemide | Furosemide | 885 | 229 |
| Losartan Potassium | Losartan Potassium | 881 | 223 |
| Carvedilol | Carvedilol | 861 | 231 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 753 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 711 | 181 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 696 | 173 |
| Xarelto | Rivaroxaban | 632 | 117 |
| Metoprolol Tartrate | Metoprolol Tartrate | 494 | 131 |
| Lisinopril | Lisinopril | 470 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 93 |
| Amiodarone Hcl | Amiodarone Hcl | 413 | 137 |
| Pravastatin Sodium | Pravastatin Sodium | 381 | 104 |
| Entresto | Sacubitril/Valsartan | 367 | 73 |
| Ranolazine Er | Ranolazine | 367 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 79 |
| Omeprazole | Omeprazole | 309 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 236 | 63 |
| Metformin Hcl | Metformin Hcl | 234 | 49 |
| Propafenone Hcl | Propafenone Hcl | 220 | 55 |
| Prasugrel Hcl | Prasugrel Hcl | 204 | 40 |
| Brilinta | Ticagrelor | 197 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 35 |
| Repatha Sureclick | Evolocumab | 175 | 32 |
| Spironolactone | Spironolactone | 169 | 43 |
| Ezetimibe | Ezetimibe | 167 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 46 |
| Simvastatin | Simvastatin | 159 | 33 |
| Atenolol | Atenolol | 153 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 151 | 35 |
| Warfarin Sodium | Warfarin Sodium | 146 | 42 |
| Famotidine | Famotidine | 142 | 29 |
| Jardiance | Empagliflozin | 136 | 27 |
| Bumetanide | Bumetanide | 122 | 30 |
| Glimepiride | Glimepiride | 119 | 25 |
| Labetalol Hcl | Labetalol Hcl | 118 | 28 |
| Trazodone Hcl | Trazodone Hcl | 118 | 20 |
| Vascepa | Icosapent Ethyl | 115 | 31 |
| Flecainide Acetate | Flecainide Acetate | 109 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 17 |
| Allopurinol | Allopurinol | 107 | 24 |
| Donepezil Hcl | Donepezil Hcl | 105 | 15 |
| Sertraline Hcl | Sertraline Hcl | 105 | 24 |
| Glipizide | Glipizide | 101 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 93 | 33 |
| Montelukast Sodium | Montelukast Sodium | 80 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 13 |
| Midodrine Hcl | Midodrine Hcl | 76 | 20 |
| Ozempic | Semaglutide | 75 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 74 | 15 |
| Valsartan | Valsartan | 69 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 20 |
| Farxiga | Dapagliflozin Propanediol | 63 | 17 |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Nitroglycerin | Nitroglycerin | 58 | 35 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | 11 |
| Sucralfate | Sucralfate | 51 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 11 |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Dofetilide | Dofetilide | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Prednisone | Prednisone | 35 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Metolazone | Metolazone | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Praluent Pen | Alirocumab | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Droxidopa | Droxidopa | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ambrisentan | Ambrisentan | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | 11 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Flurbiprofen | Flurbiprofen | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Penicillamine | Penicillamine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,331.72 · 60 records | Novo Nordisk Inc | BRILINTA, CAMZYOS, COBALT DR MRI SURESCAN, CONFIRM RX, COREVALVE EVOLUT R, Cologuard Collection Kit, ELIQUIS, FFRct, GALLANT, JARDIANCE, Kerendia, Korlym, LEQVIO, LifeVest, NURTEC ODT, NUZYRA, Ozempic, REPATHA, Rybelsus, VERQUVO, WATCHMAN, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error